Seres Therapeutics Inc Stock Price, News & Analysis

Seres Therapeutics, Inc. (Nasdaq: MCRB) has announced the successful enrollment of 201 patients in the Phase 2b ECO-RESET clinical trial for SER-287, targeting mild-to-moderate ulcerative colitis (UC). This study aims to assess clinical remission and endoscopic improvement after treatment. The FDA has indicated that this trial may support a Biologics License Application (BLA). The company anticipates sharing topline results in mid-2021, highlighting SER-287's potential as a new therapeutic approach amidst a significant unmet need for safer UC treatments.

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced its participation in two upcoming investor conferences. The Cowen 41^st Annual Health Care Conference is set for March 2, 2021, featuring a Microbiome panel discussion and 1x1 meetings. The Chardan 3^rd Annual Microbiome Medicines Summit will take place on March 8, 2021, where management will present a corporate overview at 2:30 p.m. ET and conduct 1x1 meetings. An audio webcast for the Chardan presentation will be available on Seres’ website. The company is at the forefront of microbiome therapeutics, with notable programs for recurrent C. difficile infection and ulcerative colitis.

Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on March 2, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full year 2020 results. The company is a leader in microbiome therapeutics, focusing on multifunctional bacterial therapeutics. Notably, Seres’ SER-109 program has shown positive pivotal clinical results and received Breakthrough Therapy and Orphan Drug designations from the FDA. Additionally, SER-287 is under Phase 2b evaluation for ulcerative colitis, while other programs are in various stages of clinical trials.

Seres Therapeutics (Nasdaq: MCRB) announced new findings from its SER-109 Phase 3 ECOSPOR III clinical study related to recurrent C. difficile infection. The study demonstrated rapid engraftment of SER-109-derived bacteria in the gastrointestinal tract, achieving significant metabolic changes that create an unfavorable environment for C. difficile growth. The data revealed an 88.9% sustained clinical response rate at eight weeks post-treatment, with no serious adverse events reported. SER-109 has received FDA Breakthrough Therapy and Orphan Drug designations.

Seres Therapeutics (Nasdaq: MCRB) announced promising results from its Phase 1b trial of SER-287 for treating active mild-to-moderate ulcerative colitis (UC). The study demonstrated a 40% clinical remission rate in patients receiving daily SER-287 compared to 0% in the placebo group. Data highlighted SER-287's safety and favorable tolerability profile, with no serious adverse events noted. The ongoing Phase 2b ECO-RESET study continues to enroll patients, aiming to provide topline results in late 2021. FDA Fast Track designation for SER-287 reinforces its potential as a transformative therapy for UC.

Seres Therapeutics (Nasdaq: MCRB) will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14 at 11:40 a.m. ET. A live audio webcast will be accessible in the ‘Investors and Media’ section of their website, with a replay available an hour post-event for 21 days.

Seres is focused on microbiome therapeutics, with its SER-109 program achieving positive pivotal clinical results for C. difficile infection and receiving FDA Breakthrough Therapy status. Other programs include SER-287 for ulcerative colitis and SER-401 for metastatic melanoma.

Seres Therapeutics (Nasdaq: MCRB) has announced participation in two virtual investor conferences. The Piper Sandler 32nd Annual Virtual Healthcare Conference will take place on December 1, 2020, featuring management in 1x1 meetings and a fireside chat available from November 23, 2020. The 3rd Annual Evercore ISI HealthCONx Virtual Conference is scheduled for December 2, 2020, also including management 1x1 meetings. Seres is a leader in microbiome therapeutics with advanced programs for recurrent C. difficile infection and ulcerative colitis.

Seres Therapeutics (MCRB) reported a net loss of $30.3 million for Q3 2020, up from $16.4 million in Q3 2019, primarily due to clinical and development expenses. The company announced that SER-109, its lead microbiome therapy, showed a 30.2% absolute reduction in recurrent C. difficile infections in its Phase 3 study, supporting its potential FDA approval. Following a successful capital raise, Seres has $320.3 million in cash, enhancing its growth prospects. Additionally, SER-287 and SER-301 are in clinical trials, advancing the company’s broad microbiome pipeline.

Seres Therapeutics (Nasdaq: MCRB) has initiated the dosing of participants in its Phase 1b trial for SER-301, aimed at treating active mild-to-moderate ulcerative colitis (UC). SER-301 is a microbiome therapeutic designed to counteract gastrointestinal inflammation and is based on insights from the earlier SER-287 trial. The study in Australia and New Zealand will involve 65 patients, focusing on safety and pharmacokinetics. Seres will receive a $10 million milestone payment from Nestlé Health Science upon trial initiation.